Outcome by primary cytogenetic subgroup. (A) Event-free survival. Five-year EFS estimates are given in Table 3, which also provides hazard ratios and P values. When compared with the control group without identified abnormalities, EFS was significantly shorter in the 3 t(4;11)/KMT2A-AFF1 (P = .027), Ho-Tr (P = .020), and 14q32/IGH (P < .001) subgroups. (B) Overall survival. Five-year OS estimates are given in Table 3, which also provides hazard ratios and P values. When compared with the control group without identified abnormalities, OS was significantly shorter in the 3 t(4;11)/KMT2A-AFF1 (P = .005), Ho-Tr (P = .007), and 14q32/IGH (P < .001) subgroups.